Exagen INC Form 4 insider transactions

Exagen's Chief Financial Officer, Jeffrey G. Black, reported significant acquisitions of restricted stock units, stock options, and common stock through an employee plan.

EXAGEN's President and CEO, John Aballi, received significant equity awards totaling 250,000 units, comprising 150,000 restricted stock units and options for 100,000 shares, aligning his interests with long-term shareholder value.

Exagen Inc. President and CEO John Aballi reported both a tax-related sale and an Employee Stock Purchase Plan acquisition of company common stock.

Exagen Inc.'s President and CEO, John Aballi, sold 11,430 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

EXAGEN's Chief Financial Officer, Jeffrey G. Black, sold 1,584 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

EXAGEN Inc. President and CEO John Aballi sold 31,787 shares of common stock at $11.8161 per share to cover tax withholding obligations from Restricted Stock Unit vesting.

EXAGEN's Chief Financial Officer, Jeffrey G. Black, sold 20,466 shares of common stock to cover tax withholding obligations related to RSU vesting.

EXAGEN Inc. Director Paul Kim filed an amended Form 4 to correct an error in his previously reported beneficial ownership of stock options, clarifying he holds 9,000 options, not 18,000.

EXAGEN Inc. Director Frank Stokes has been granted 9,000 stock options with an exercise price of $7.36, aligning his interests with shareholder value.

EXAGEN Inc. Director Paul Kim was granted 9,000 stock options with an exercise price of $7.36, increasing his total beneficial ownership of derivative securities to 18,000.

Exagen Inc. Director and 10% Owner Scott D. Kahn has acquired 9,000 stock options with an exercise price of $7.36, as reported in a recent SEC Form 4 filing.

Exagen Inc. Director Ana Hooker was granted 9,000 stock options with an exercise price of $7.36, vesting on the first anniversary of the grant date or the next annual meeting.

EXAGEN Inc. Director Tina Susan Nova has acquired 13,500 stock options with an exercise price of $7.36, as reported in a recent SEC Form 4 filing, signaling continued alignment with the company's long-term performance.

NMSIC Co-Investment Fund, L.P. reports the sale of 350,000 shares of Exagen Inc. common stock at $3.3 per share on March 25, 2025.

Exagen Inc.'s CEO, John Aballi, reports the acquisition of company shares through the Employee Stock Purchase Plan (ESPP).

Chief Financial Officer Jeffrey G. Black of Exagen Inc. reports the acquisition of 15,000 shares of common stock and 10,000 stock options on February 21, 2025.

John Aballi, President and CEO of Exagen Inc., reports the acquisition of restricted stock units and stock options, signaling changes in his beneficial ownership of the company's securities.

John Aballi, President and CEO of Exagen Inc., files an amendment to a previous Form 4 to correct the number of directly and indirectly owned shares of common stock.

NMSIC Co-Investment Fund, a 10% owner of Exagen Inc., sold 200,000 shares of common stock at a price of $3.3002 per share.

Exagen Inc.'s Chief Financial Officer, Jeffrey G. Black, acquired 22,298 shares of common stock at an average price of $2.98 on November 15, 2024.

Exagen Inc.'s CEO, John Aballi, sold 24,305 shares of common stock at an average price of $2.81 per share on November 14, 2024.

Chief Financial Officer of Exagen Inc., Jeffrey G. Black, reports acquiring 225,000 shares of common stock and disposing of 252,194 shares on September 1, 2024.

Director Kahn Scott D acquired stock options in Exagen Inc. on June 10, 2024.

Frank Stokes, a director of Exagen Inc., acquired 9,000 stock options at an exercise price of $1.99 on June 10, 2024.

Director Ana Hooker acquired 9,000 stock options in Exagen Inc. on June 10, 2024, at an exercise price of $1.99.

Director Paul Kim acquired 9,000 stock options in Exagen Inc. on June 10, 2024, at an exercise price of $1.99.

Director Tina Susan Nova acquired 13,500 stock options in Exagen Inc. on June 10, 2024, at an exercise price of $1.99.

Exagen Inc.'s President and CEO, John Aballi, recently purchased 40,401 shares of the company's common stock at a price of $1.92 per share.

Kamal Adawi, CFO of Exagen Inc., sold shares of common stock on March 4, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Exagen Inc.'s CEO, John Aballi, acquired 9,804 shares of common stock through the Employee Stock Purchase Plan at a price of $1.91 per share on February 29, 2024, increasing his direct holdings to 600,788 shares.